249 related articles for article (PubMed ID: 21343917)
21. Potential Therapeutic Approach using Aromatic l-amino Acid Decarboxylase and Glial-derived Neurotrophic Factor Therapy Targeting Putamen in Parkinson's Disease.
Tripathi RK; Goyal L; Singh S
Curr Gene Ther; 2024; 24(4):278-291. PubMed ID: 38310455
[TBL] [Abstract][Full Text] [Related]
22. Increased brain bio-distribution and chemical stability and decreased immunogenicity of an engineered variant of GDNF.
Smith RC; O'Bryan LM; Mitchell PJ; Leung D; Ghanem M; Wilson JM; Hanson JC; Sossick S; Cooper J; Huang L; Merchant KM; Lu J; O'Neill MJ
Exp Neurol; 2015 May; 267():165-76. PubMed ID: 25771799
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.
San Sebastian W; Richardson RM; Kells AP; Lamarre C; Bringas J; Pivirotto P; Salegio EA; Dearmond SJ; Forsayeth J; Bankiewicz KS
Hum Gene Ther; 2012 Feb; 23(2):210-7. PubMed ID: 22017504
[TBL] [Abstract][Full Text] [Related]
24. Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery.
Drinkut A; Tereshchenko Y; Schulz JB; Bähr M; Kügler S
Mol Ther; 2012 Mar; 20(3):534-43. PubMed ID: 22086235
[TBL] [Abstract][Full Text] [Related]
25. Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study.
Bäckman CM; Shan L; Zhang YJ; Hoffer BJ; Leonard S; Troncoso JC; Vonsatel P; Tomac AC
Mol Cell Endocrinol; 2006 Jun; 252(1-2):160-6. PubMed ID: 16644101
[TBL] [Abstract][Full Text] [Related]
26. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.
Warren Olanow C; Bartus RT; Baumann TL; Factor S; Boulis N; Stacy M; Turner DA; Marks W; Larson P; Starr PA; Jankovic J; Simpson R; Watts R; Guthrie B; Poston K; Henderson JM; Stern M; Baltuch G; Goetz CG; Herzog C; Kordower JH; Alterman R; Lozano AM; Lang AE
Ann Neurol; 2015 Aug; 78(2):248-57. PubMed ID: 26061140
[TBL] [Abstract][Full Text] [Related]
27. Insights from mathematical modeling for convection-enhanced intraputamenal delivery of GDNF.
Belova E; Shaffer CL; Trapa PE
Med Biol Eng Comput; 2017 Dec; 55(12):2069-2077. PubMed ID: 28493093
[TBL] [Abstract][Full Text] [Related]
28. Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease.
Du Y; Zhang X; Tao Q; Chen S; Le W
Neurodegener Dis; 2013; 11(3):113-28. PubMed ID: 22626907
[TBL] [Abstract][Full Text] [Related]
29. Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.
Heiss JD; Ray-Chaudhury A; Kleiner DE; Ehrlich DJ; Scott G; Edwards NA; Goldstein DS; Hammoud DA; Hadaczek P; Van Laar VS; Graff SA; Herscovitch P; Lungu C; Hallett M; Lonser RR; Zaghloul KA; Bankiewicz KS
Mov Disord; 2024 May; ():. PubMed ID: 38718138
[TBL] [Abstract][Full Text] [Related]
30. T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery.
Richardson RM; Gimenez F; Salegio EA; Su X; Bringas J; Berger MS; Bankiewicz KS
Neurosurgery; 2011 Jul; 69(1):154-63; discussion 163. PubMed ID: 21430597
[TBL] [Abstract][Full Text] [Related]
31. AAV2-GDNF gene therapy for Parkinson's disease.
Even Ram S; Galun E
Hum Gene Ther; 2009 May; 20(5):430-1. PubMed ID: 19438403
[No Abstract] [Full Text] [Related]
32. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
J Neurosurg; 2007 Apr; 106(4):614-20. PubMed ID: 17432712
[TBL] [Abstract][Full Text] [Related]
33. GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop.
Barker RA; Björklund A; Gash DM; Whone A; Van Laar A; Kordower JH; Bankiewicz K; Kieburtz K; Saarma M; Booms S; Huttunen HJ; Kells AP; Fiandaca MS; Stoessl AJ; Eidelberg D; Federoff H; Voutilainen MH; Dexter DT; Eberling J; Brundin P; Isaacs L; Mursaleen L; Bresolin E; Carroll C; Coles A; Fiske B; Matthews H; Lungu C; Wyse RK; Stott S; Lang AE
J Parkinsons Dis; 2020; 10(3):875-891. PubMed ID: 32508331
[TBL] [Abstract][Full Text] [Related]
34. Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys.
Maswood N; Grondin R; Zhang Z; Stanford JA; Surgener SP; Gash DM; Gerhardt GA
Neurobiol Aging; 2002; 23(5):881-9. PubMed ID: 12392792
[TBL] [Abstract][Full Text] [Related]
35. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys.
Gerhardt GA; Cass WA; Huettl P; Brock S; Zhang Z; Gash DM
Brain Res; 1999 Jan; 817(1-2):163-71. PubMed ID: 9889359
[TBL] [Abstract][Full Text] [Related]
36. Optimized cannula design and placement for convection-enhanced delivery in rat striatum.
Yin D; Forsayeth J; Bankiewicz KS
J Neurosci Methods; 2010 Mar; 187(1):46-51. PubMed ID: 20026357
[TBL] [Abstract][Full Text] [Related]
37. SINEUP Non-coding RNA Targeting GDNF Rescues Motor Deficits and Neurodegeneration in a Mouse Model of Parkinson's Disease.
Espinoza S; Scarpato M; Damiani D; Managò F; Mereu M; Contestabile A; Peruzzo O; Carninci P; Santoro C; Papaleo F; Mingozzi F; Ronzitti G; Zucchelli S; Gustincich S
Mol Ther; 2020 Feb; 28(2):642-652. PubMed ID: 31495777
[TBL] [Abstract][Full Text] [Related]
38. Intermittent convection-enhanced delivery of GDNF into rhesus monkey putamen: absence of local or cerebellar toxicity.
Luz M; Allen PC; Bringas J; Boiko C; Stockinger DE; Nikula KJ; Lewis O; Woolley M; Fibiger HC; Bankiewicz K; Mohr E
Arch Toxicol; 2018 Jul; 92(7):2353-2367. PubMed ID: 29785638
[TBL] [Abstract][Full Text] [Related]
39. Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.
Whone AL; Boca M; Luz M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
J Parkinsons Dis; 2019; 9(2):301-313. PubMed ID: 30829619
[TBL] [Abstract][Full Text] [Related]
40. Continuous intranigral infusion is not associated with observable behavioral deficits or marked pathology: a preclinical safety study.
Grondin R; Ai Y; Hardy PA; Butt MT; Nelson BD; Lemmon JD; Bumcrot D; Gash DM; Gerhardt GA; Zhang Z
J Neurosurg; 2017 Apr; 126(4):1253-1262. PubMed ID: 27231974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
